Exenatide-Loaded PLGA Microspheres for Islet Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for type 1 diabetes management, such as insulin administration and whole pancreas transplantation, are suboptimal due to complications and limited donor availability, while allogeneic islet transplantation faces challenges like graft failure and hypoxia, necessitating improved strategies for islet survival and function.
Innovation Solution
The use of exenatide-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres as intracapsular drug depots within alginate microcapsules for sustained, localized release of exenatide to enhance the viability and insulin-secretion function of porcine islets, mitigating systemic adverse effects and hypoxic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If encapsulated islets are transplanted to treat type 1 diabetes, then diabetes management is improved, but graft failure and hypoxia occur reducing survival time
Solution Approach 1:
The patent applies preliminary action by incorporating exenatide-loaded PLGA microspheres into the alginate microcapsules before transplantation. This pre-loading ensures that exenatide is immediately available to protect the islets from hypoxia and oxidative stress during the critical early post-transplantation period, thereby improving graft survival and extending functional duration
Solution Approach 2:
The patent uses exenatide as an intermediary substance that mediates protection between the harmful hypoxic environment and the vulnerable transplanted islets. Exenatide reduces oxidative stress and improves islet survival, acting as a protective intermediary that extends graft functionality over time
2Reliability
If exenatide is administered systemically to improve islet survival, then islet function is enhanced, but adverse systemic effects occur
Solution Approach 1:
The patent applies local quality by delivering exenatide locally at the transplantation site through intracapsular microspheres rather than systemic administration. This localized delivery concentrates the protective effect where needed (around the islets) while minimizing exposure to other tissues, thereby reducing adverse systemic effects
Solution Approach 2:
The PLGA microsphere acts as an intermediary delivery vehicle that localizes exenatide release to the immediate vicinity of the islets. This intermediary system ensures that exenatide benefits the islets without causing widespread systemic exposure and associated adverse effects
3Manufacturing precision
If whole pancreas transplantation is performed to achieve tight glucose control, then glycemic control is improved, but surgical complications and immunosuppression increase morbidity
Solution Approach 1:
The patent applies segmentation by using isolated islets instead of whole pancreas transplantation. This segmentation approach extracts only the functional insulin-producing units from the pancreas, enabling transplantation without the need for complex surgical procedures, thereby maintaining glycemic control precision while reducing surgical complications and immunosuppression requirements
Solution Approach 2:
The alginate microcapsule acts as an intermediary that protects transplanted islets from immune attack without requiring systemic immunosuppression. This intermediary barrier enables islet transplantation with minimal complications while maintaining effective glucose control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the survival and function of encapsulated islets by providing sustained exenatide release, potentially extending graft survival and reducing complications, thus offering a promising alternative for diabetes treatment.
Implementation Method 1
exenatide-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres (MSs) as intracapsular drug depots. The PLGA MSs were monodisperse, exhibiting sustained exenatide release during the 21-day period
Implementation Method 2
porcine islets co-encapsulated with the exenatide-loaded PLGA MSs in alginate microcapsules
Data Source
AI summary
Provided is a microcapsule for increasing the survival and/or function of a cell, such as an islet cell, microcapsule can include an outer shell comprising a first polymer; an interior core comprising: at least one live cell; a second polymer; and at least one microsphere comprising a third polymer and a compound capable of improving survival of the at least one cell. The improved survival and/or function of the at least one live cell in the microcapsule is compared to a live cell in a microcapsule in the absence of the compound capable of improving survival of the at least one cell. The first and second polymer may include alginate and the third polymer (used for the microsphere) may comprise PLGA. The compound may include a GLP-1 receptor agonist. Also provided are methods for producing such microcapsules; insulin delivery systems using the microcapsules, and methods to treat disease, such as diabetes, using the microcapsules.